Linde plc
Capital-intensive, contract-anchored industrial-gas supply: on-site plants (long-term take-or-pay, cost pass-through), merchant (bulk/cryogenic delivery) and packaged-gas (cylinders), plus Linde Engineering (plant EPC). Density of pipelines/plants + 15-20 year contracts produce recurring, inflation-protected cash flows.
Earnings, margins, COGS & capex
Slow top-line grower (low-single-digit organic, volume-flat) that manufactures double-digit EPS growth via relentless pricing above inflation, productivity savings, disciplined capital allocation and share buybacks. Best-in-class margins and returns on capital in the gases oligopoly; ~30% adjusted operating margin. Cash generative enough to fund $5B+ annual capex, a growing dividend and large buybacks simultaneously.
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~96¢ is cost of goods and ~0¢ operating expense, leaving ~4¢ of operating profit (~23¢ net).
Revenue trend
Margins
FY2025 +30bps YoY; Q1-2026 flat YoY (-10bps); FY26 guide margin expansion at/above upper end of 40-60bps target
rising
stable-to-up
stable
COGS structure
Cost base dominated by electricity/energy (air separation is highly power-intensive) and, for hydrogen/CO, natural-gas feedstock; on-site contracts pass energy and inflation through to customers, insulating margins. Other inputs: logistics/distribution fleet, plant maintenance, labor. Productivity programs are a structural annual margin lever.
Capex
FY2025 capex $5.26B (~15.5% of sales); FY2026 guide $5.0-5.5B. Growth capex is contracted before spend — on-site projects only sanctioned against signed take-or-pay offtake, keeping ROC high and de-risking the backlog. Sale-of-gas project backlog ~$7.1B; total backlog >$10B.
Latest earnings
Beat on the lines, missed on the margin. Sales $9,289M and adjusted EPS $4.50 (+10% YoY) came in above the Street and above Linde's own $4.40-$4.50 Q2 guide; reported EPS $4.15 was +11%. But adjusted operating margin was 29.5%, 60bps below prior year — the release attributes it to 'higher price and productivity initiatives … offset by cost inflation'. The shares closed down 5.9% on the day
Q3-2026 adjusted EPS $4.45-$4.55, up 6-8% YoY, with no expected currency impact. FY2026 adjusted EPS $17.70-$17.90, up 8-9% assuming 1% favorable currency — the low end raised from $17.60 at Q1. FY2026 capex raised to $5.5-6.0B (from $5.0-5.5B). On the call management reiterated a long-term 8-12% EPS growth algorithm and said it remains 'confident in our long-term margin expansion story'; the Q2 release itself carries no margin-expansion target
- Q2-2026 sales
- $9,289M (+9% reported, +4% underlying)
- Q2-2026 adjusted operating profit
- $2,744M (+7%)
- Q2-2026 adjusted operating margin
- 29.5% (-60bps YoY)
- Q2-2026 adjusted EPS
- $4.50 (+10%)
- Sale-of-gas project backlog
- $8.1B — a record, up ~$1B on a US electronics win (total project backlog $11B)
- Q2-2026 free cash flow
- $833M (OCF $2,271M less capex $1,438M)
- Q2-2026 shareholder returns
- $1,590M in dividends and buybacks, net of issuances
- Return on capital
- 23.5% (non-GAAP, per CEO commentary)
- Segment operating margins Q2-2026
- Americas 31.2% (-50bps), EMEA 35.7% (-40bps), APAC 28.4% (-120bps), Engineering 16.0%
Growth drivers
- Pricing above inflation every year (contractual escalators + merchant/packaged price attainment) — the primary EPS engine given flat volumes
- Clean-hydrogen and carbon-capture project pipeline (blue/green H2, CCS with energy/chemical majors) as multi-decade backlog
- Electronics/semiconductor gases (bulk specialty + rare gases) riding fab buildout (US CHIPS, TSMC/Intel/Samsung/Micron)
- Productivity/cost-out programs compounding margin ~40-60bps/yr
- Bolt-on M&A and buybacks (net $7.4B returned to shareholders FY2025) shrinking share count
- Backlog conversion: >$10B of contracted projects starting up over coming years
Reported financials — SEC EDGAR
Audited GAAP figures pulled from SEC filings · latest filing 2026-02-25. The audited primary-source spine — not financial advice.
Revenue — annual (GAAP)
Margins & balance sheet — FY’25
Bull & bear
The gases oligopoly still compounds: Q2 delivered +10% adjusted EPS, a record $8.1B sale-of-gas backlog and 23.5% return on capital, and — for the first time in a while — volumes contributed as much as price. The electronics build-out is turning into contracted, take-or-pay revenue faster than the market is crediting, and the multiple has come in to ~27x forward from ~31x.
- The EPS algorithm is intact and the guide went up, not down: adjusted EPS $4.50 (+10%) in Q2, FY2026 guidance low end raised to $17.70-$17.90 (+8-9%) from $17.60-$17.90
- Growth is no longer purely price-led — Q2 underlying sales of +4% split evenly between 2% price and 2% volumes, versus 2% price / 1% volume in Q1
- Backlog is at a record and is being fed by the strongest end market: sale-of-gas backlog rose ~$1B to $8.1B on a US electronics win, with total project backlog at $11B; electronics grew ~18% YoY and management expects it to remain the largest backlog contributor
- The semiconductor tie-in got concrete and contracted: a $1B Phoenix expansion (two new SPECTRA air separation units) under a new long-term ultra-high-purity supply agreement, plus ~$800M at the Linde LienHwa Taiwan JV for the same customer — capital committed only against signed offtake
- The margin problem is identified and ring-fenced, not diffuse: the drag is the US home-care (Lincare) business inside Americas, and management is explicitly evaluating 'the strategic fit of this U.S. home care business within Linde, both in part and as a whole' — a divestiture would remove the drag rather than manage it
- Valuation has already de-rated: ~26.9x the FY2026 adjusted-EPS guidance midpoint ($478.38 / $17.80) versus ~31x when the shares were near their Jul 2 high, on unchanged earnings power
The distinctive part of the Linde story — margin expansion compounding every year on top of low-single-digit organic growth — has now failed two quarters running, while capex guidance went up and free-cash conversion went down. You are still paying ~27x forward for a mid-single-digit organic grower whose fix depends on selling a business it has not yet sold.
- Adjusted operating margin fell 60bps YoY to 29.5% in Q2, after -10bps in Q1 — two consecutive quarters of contraction against a franchise thesis built on 40-60bps of annual expansion; the release attributes it to cost inflation outrunning price and productivity
- The deterioration is broad across segments, not one-off: Americas -50bps, EMEA -40bps, APAC -120bps, Engineering -30bps, and adjusted EBITDA margin fell to 38.5% from 39.4%
- Cash conversion is weakening: 1H-2026 FCF margin was 9.6% versus 15.0% for FY2025, and the FY2026 capex guide was raised to $5.5-6.0B from $5.0-5.5B — more capital in, less cash out, for the same guided EPS
- Net debt rose to ~$23.1B while the company kept returning $1.59B/quarter to shareholders — the buyback contribution to EPS growth is increasingly debt-funded as capex climbs
- The Lincare remedy is a plan, not an event: the CFO would not quantify the drag beyond agreeing it was 'probably higher' than an analyst's $30M-per-quarter estimate, the unit is not broken out in the segment tables, and a strategic review can end in no transaction
- Cost pass-through mechanics cut both ways — management's own bridge shows margin optics distorted by pass-through, and prolonged inflation without matching price attainment compresses the spread the whole model rests on
What it is worth
Forward P/E and quality-compounder framing (peer-relative to APD, Air Liquide); EV/EBITDA cross-check
Multiple compresses toward the low-20s on an industrial recession, a pricing-discipline break, or hydrogen-capex disappointment — a ~25-30% derating even before any earnings miss, given the rich starting point.
~30-31x forward EPS holds
total return tracks ~7-9% EPS growth plus ~1-2% dividend/buyback yield — roughly high-single/low-double-digit annualized, in line with the earnings algorithm.
Sustained ~8-10% EPS compounding + margin expansion + hydrogen/CCS backlog optionality supports a mid-$600s+ level over time as EPS grows into the multiple (Citi PT $600); quality re-rating if the transition backlog is recognized as recurring.
At ~$547 and FY2026 adj. EPS midpoint ~$17.75, LIN trades at ~31x forward earnings — a premium justified by best-in-class ~30% margins, high ROC, contract-anchored recurring cash flows and a consistent ~7-9% EPS-growth algorithm. The premium is the risk: it prices continued flawless pricing/productivity execution and leaves little multiple cushion.
SWOT
Strengths
- Global #1 in industrial gases with dense local plant/pipeline networks that are near-impossible to replicate
- ~30% adjusted operating margin and top-tier return on capital — best in the peer set
- Contract structure (15-20yr take-or-pay, energy/inflation pass-through) makes revenue and margin recurring and defensive
- Fortress balance sheet (A/A2), $10.4B operating cash flow funding capex + dividend + buybacks simultaneously
- Backlog >$10B of pre-contracted growth projects; disciplined only-build-against-offtake capital allocation
Weaknesses
- Structurally low volume growth — GDP-and-below organic; EPS growth leans heavily on price and buybacks
- High capital intensity (~15-16% of sales) ties up cash and lengthens payback
- Energy-cost exposed; margin depends on pass-through discipline holding through price spikes
- Cyclical end-markets (steel, chemicals, metals, manufacturing) can soften merchant volumes
- Large size means M&A and new-project needle-moving is harder; law of large numbers on growth
Opportunities
- Clean hydrogen (blue/green) and carbon capture — decades of potential contracted backlog if the energy transition scales
- Semiconductor/electronics gas demand from the global fab buildout
- Continued pricing power and productivity compounding margins upward
- Emerging-market industrialization and on-site conversions of self-generated gas users
- Bolt-on consolidation of regional/packaged-gas players
Threats
- Prolonged industrial recession compressing merchant/packaged volumes and pricing
- Energy-price shocks outrunning contractual pass-through timing
- Hydrogen-economy timelines slipping — stranded/under-utilized clean-H2 capex risk
- FX translation drag (large ex-US footprint) on USD-reported results
- Regulatory/antitrust limits on further consolidation in a concentrated oligopoly
Moats, dependencies & bottlenecks
Moats
On-site plants and merchant/pipeline density create effective local monopolies; a competitor cannot economically overbuild an installed customer cluster.
15-20yr per contract Volume and energy/inflation pass-through locked contractually; revenue is recurring and de-risked.
Largest player globally; procurement, engineering (Linde Engineering builds its own plants) and productivity programs give a structural cost edge.
Three players (Linde, Air Liquide, Air Products) dominate globally; rational pricing and high entry barriers.
Moderate-strong Contract-length On-site integration and reliability-critical supply make customers extremely sticky.
Dependencies
Air separation is power-intensive; margins depend on energy pass-through holding. Natural gas is feedstock for hydrogen/CO.
Steel, chemicals, refining, metals and manufacturing drive merchant/packaged volumes.
Specialty and rare-gas demand tracks fab construction and utilization.
Clean-H2/CCS backlog conversion depends on subsidies, offtake and cost curves materializing on schedule.
Large non-USD revenue base creates translation volatility.
Advantages
- Largest scale and densest network in a three-player global oligopoly
- ~30% adjusted operating margins, top-tier ROC and cost leadership
- Contract-anchored, inflation-protected recurring cash flows
- In-house plant engineering (Linde Engineering) lowering build cost and control
- Fortress balance sheet enabling simultaneous capex, dividend growth and buybacks
Weaknesses
- Structurally low organic volume growth (GDP-and-below)
- High capital intensity and long paybacks
- Energy-cost sensitivity if pass-through timing lags
- Cyclicality in industrial end-markets
- Premium valuation limits multiple upside
Bottlenecks
- Long project lead times and permitting for new on-site plants and hydrogen/CCS facilities
- Capital availability discipline — growth gated by signed offtake, capping how fast backlog can be added
- Power availability/cost at plant locations for energy-intensive air separation
- Skilled engineering/EPC capacity within Linde Engineering to execute the backlog
- Grid/renewable-power access constraining green-hydrogen economics
Top signals & trends
Top signals
Reaffirms the high-single/double-digit-through-cycle EPS algorithm despite flat volumes.
Best-in-class level, but flat-to-down 10bps YoY in the quarter; full-year expansion still guided via pricing + productivity.
Confirms organic growth is price-led, not volume-led — the core bear point.
Visible, contracted future revenue underpinning growth capex.
Quality is recognized; valuation leaves little cushion.
Capital-return discipline supports per-share compounding.
Trends
Positive (long-dated) · Potential multi-decade backlog; also the largest source of capex-risk if timelines slip.
Rising demand for bulk specialty and rare gases.
Contractual escalators let Linde price above inflation, supporting margin.
Merchant and packaged volumes exposed to global industrial cycle.
Higher power costs pressure air-separation economics; green-H2 needs cheap renewables.
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Electric utilities / independent power producers Largest input — power for energy-intensive air separation (e.g. NextEra NEE, regional utilities, PPAs).
Feedstock for hydrogen/CO production via SMR.
Linde Engineering (internal) + equipment/compressor OEMs Plant EPC largely in-house; buys compressors, steel, cryogenic equipment externally.
Cryogenic tanker and cylinder distribution fleet for merchant and packaged gas.
Refining/chemicals offtake and clean-hydrogen/CCS partner.
Chemical majors buying oxygen, nitrogen, hydrogen on-site.
Semiconductor fabs consuming bulk specialty, nitrogen and rare gases.
Nucor, ArcelorMittal) Oxygen and industrial gases for steelmaking and metal fabrication.
Medical oxygen and respiratory gases — stable, non-cyclical demand.
Nitrogen/CO2 for freezing, packaging and process use.
US-listed #3 global industrial gas major; heavier bet on large-scale clean-hydrogen mega-projects (some execution/return concerns).
French-listed #2 globally and Linde's closest peer in scale, margins and network density; direct oligopoly rival.
Japan-listed #4 global player (Matheson in the US); strong in electronics gases in Asia and North America.
Large privately held (family-owned) European/Americas industrial-gas player; regional competitor, not listed.
Japan-listed; leading in hydrogen and packaged gases in Japan.